10-QHealthcare

Halozyme Therapeutics, Inc.

HALO · Period ending 2026-09-30 · Filed 2026-11-05 · Updated

In short

Halozyme Therapeutics, Inc. (HALO) has revenue up 37.6% to $1.4B and net income down 28.6% to $316.9M year on year. Its net margin is 22.7%, and it trades at 36.0× trailing earnings. Fisclear flags 1 high-severity risk, led by: Total liabilities are 98% of total assets — the balance sheet is heavily leveraged with limited equity cushion. How we calculate this

Valuation

Healthcare
Live · Yahoo Finance

Price

$91.35

P/E (TTM)

22.8x

Price ÷ earnings per share

P/B

97.7x

Price ÷ book value

P/S (TTM)

5.8x

Price ÷ revenue per share

Beta

0.90

Moderate market correlation

52-Week Range

$61.23$91.35 now$134.00

Decision Context

Market appears to be pricing in less growth than this company's historical average, suggesting potential upside if the trajectory continues. Quality and efficiency scores support the business case.

Based on filing period ending Sept 2026

FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.

HALO vs

Macro Context

Fed Funds Rate

3.88%

Accommodative

10-Year Treasury

5.13%

2026-10-01

Unemployment

4.2%

Near full employment

CPI Index

336.3

2026-09-01

M2 Money Supply

$23.4T

2026-09-01

The Federal Funds rate stands at 3.88% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 5.13%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.2%; Industrial production index is at 104.0; M2 money supply is $23.4T; CPI index stands at 336.3.

SWOT Analysis — HALO

Inflationary Boom
Macro lens (Inflationary Boom): Rising costs and tighter margins amplify financial risks in this regime.
✦

Strengths

  • Revenue: $1.4B (+37.6% YoY) — Revenue grew 38% — the company sold more goods or services than the prior year.

  • Operating Cash Flow: $651.6M (+36.0% YoY) — Operating cash flow grew 36% — the business generated more cash from day-to-day operations.

  • Total Assets: $2.5B (+22.4% YoY) — Total assets grew 22% — the company's resource base expanded.

◈

Weaknesses

  • Net Income: $316.9M (-28.6% YoY) — Profit fell 29% but remained positive.

  • EPS (Diluted): $2.56 (-25.4% YoY) — Earnings per share fell 25%.

◎

Opportunities

No clear opportunities identified at this time.

⚠

Threats

  • Total liabilities are 98% of total assets — the balance sheet is heavily leveraged with limited equity cushion.

Year-over-Year Changes

Revenue

$1.4B

was $1.0B

+37.6%

Revenue grew 38% — the company sold more goods or services than the prior year.

Operating Cash Flow

$651.6M

was $479.1M

+36.0%

Operating cash flow grew 36% — the business generated more cash from day-to-day operations.

Net Income

$316.9M

was $444.1M

−28.6%

Profit fell 29% but remained positive.

EPS (Diluted)

$2.56

was $3.43

−25.4%

Earnings per share fell 25%.

Total Assets

$2.5B

was $2.1B

+22.4%

Total assets grew 22% — the company's resource base expanded.

Risk Flags

1 high · 0 medium · 0 low
  • ⚠ High

    Total liabilities are 98% of total assets — the balance sheet is heavily leveraged with limited equity cushion.

Technical Signals

Daily closes · 1-year data

Halozyme Therapeutics, Inc.: common questions

Is Halozyme Therapeutics, Inc. profitable?

Yes. Halozyme Therapeutics, Inc. made a net profit of $317M in its latest fiscal year (fiscal 2025), a net margin of 22.7%.

Is Halozyme Therapeutics, Inc.'s revenue growing?

Yes. Revenue grew 37.6% year on year, to $1.4B.

What is Halozyme Therapeutics, Inc.'s P/E ratio?

Halozyme Therapeutics, Inc. trades at 22.8× its trailing twelve-month earnings. In other words, the share price is about 23 times the profit per share the company earned over the past year.

Does Halozyme Therapeutics, Inc. pay a dividend?

No dividend is currently expected from Halozyme Therapeutics, Inc., according to the latest market data.

What are the main risks for Halozyme Therapeutics, Inc.?

Fisclear's checks flag 1 medium- or high-severity risk. The most serious: Total liabilities are 98% of total assets — the balance sheet is heavily leveraged with limited equity cushion.

Answers are generated from the figures in this report (updated 6 Nov 2026). Information, not investment advice.

Latest News

via Finnhub

Filing History — HALO

Get the weekly digest

5 company reports + macro context every week, free. No spam.

  • Unlimited goal simulations
  • 5 free company report summaries per day
  • Weekly financial insights newsletter

External Links

Trade HALO

Links open broker research pages. Not an endorsement or recommendation.

Research Halozyme Therapeutics, Inc.

Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.